FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1035-1036 September 26, 2002 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Warren, H. S. Related Article by Siegel, J. P. PubMed Citation

To the Editor: In this issue of the Journal, Warren et al.¹ and Siegel² offer their views on the approval of drotrecogin alfa (activated), or recombinant human activated protein C, for the treatment of severe sepsis. We concur with Dr. Siegel's comments regarding the extensive testing to ensure the potency and consistency of drotrecogin alfa (activated) used in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.³ It is fortunate that the master cell bank used to produce the drug administered in the latter portion of the trial will be sufficient to meet clinical needs for . . . [Full Text of this Article]

This article has been cited by other articles:

• Bridges, E. J., Dukes, S. (2005). Cardiovascular Aspects of Septic Shock: Pathophysiology, Monitoring, and Treatment. Crit Care Nurse 25: 14-40 [Full Text]  
• Jeschke, M. G., Klein, D., Bolder, U., Einspanier, R. (2004). Insulin Attenuates the Systemic Inflammatory Response in Endotoxemic Rats. Endocrinology 145: 4084-4093 [Abstract] [Full Text]  
• Gropper, M. A. (2004). Evidence-Based Management of Critically Ill Patients: Analysis and Implementation. Anesth. Analg. 99: 566-572 [Abstract] [Full Text]  
• Tracy, R. P. (2003). Thrombin, Inflammation, and Cardiovascular Disease: An Epidemiologic Perspective. Chest 124: 49S-57S [Abstract] [Full Text]  
• Pastores, S M (2003). Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Postgrad. Med. J. 79: 5-10 [Abstract] [Full Text]  
• (2002). Activated Protein C -- How Should We Use It to Treat Sepsis?. JWatch Infect. Diseases 2002: 3-3 [Full Text]